Division of Gastroenterology, Hepatology and Motility, The University of Kansas School of Medicine, Kansas City, Kansas, USA.
Department of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, USA.
J Gastroenterol Hepatol. 2024 Jan;39(1):141-148. doi: 10.1111/jgh.16362. Epub 2023 Sep 24.
BACKGROUND/OBJECTIVES: We aimed to assess 30-day readmissions of endoscopic retrograde cholangiopancreatography (ERCP) in the United States.
The National Readmission Database was utilized from 2016 to 2020 to identify 30-day readmissions of ERCP. Hospitalization characteristics and outcomes were compared between index hospitalizations and readmissions. Predictors of 30-day readmission and mortality were also identified.
Between 2016 and 2020, 885 416 index hospitalizations underwent ERCP. Of these, 88 380 (10.15%) were readmitted within 30 days. Compared to index hospitalizations, 30-day readmissions had higher mean age (63.76 vs 60.8 years, P < 0.001) and proportion of patients with Charlson Comorbidity Index (CCI) score ≥3 (48.26% vs 29.91%, P < 0.001). Sepsis was the most common readmission diagnosis. Increasing age, male gender, higher CCI scores, admissions at large metropolitan teaching hospitals, cholecystectomy on index hospitalization, biliary stenting, increasing length of stay (LOS) at index admission, post-ERCP pancreatitis, post-ERCP hemorrhage, and gastrointestinal tract perforation were independent predictors of 30-day readmissions. Furthermore, 30-day readmissions had higher odds of inpatient mortality (4.42% vs 1.66%, aOR 1.9, 95% CI: 1.79-2.01, P < 0.001) compared to index hospitalizations. However, we noted a shorter LOS (5.78 vs 6.22 days, mean difference 1.2, 95% CI: 1.12-1.28, P < 0.001) and lower total hospital charge ($71 076 vs $93 418, mean difference $31 452, 95% CI: 29 835-33 069, P < 0.001) for 30-day readmissions compared to index hospitalizations. Increasing age, higher CCI scores, increasing LOS, biliary stenting, and post-ERCP hemorrhage were independent predictors of inpatient mortality for 30-day readmissions.
After index ERCP, the 30-day remission rate was 10.15%. Compared to index hospitalizations, 30-day readmissions had higher odds of inpatient mortality.
背景/目的:我们旨在评估美国内镜逆行胰胆管造影术(ERCP)的 30 天再入院率。
利用 2016 年至 2020 年的国家再入院数据库,确定 ERCP 的 30 天再入院病例。比较指数住院和再入院之间的住院特征和结局。还确定了 30 天再入院和死亡率的预测因素。
2016 年至 2020 年期间,885416 例指数住院患者接受了 ERCP。其中,88380 例(10.15%)在 30 天内再次入院。与指数住院相比,30 天再入院的平均年龄更高(63.76 岁 vs 60.8 岁,P<0.001),Charlson 合并症指数(CCI)评分≥3 的患者比例更高(48.26% vs 29.91%,P<0.001)。败血症是最常见的再入院诊断。年龄增长、男性、CCI 评分较高、在大型都市教学医院就诊、指数住院行胆囊切除术、胆道支架置入术、指数住院时长增加、ERCP 后胰腺炎、ERCP 后出血和胃肠道穿孔是 30 天再入院的独立预测因素。此外,与指数住院相比,30 天再入院的住院死亡率更高(4.42% vs 1.66%,比值比 1.9,95%置信区间:1.79-2.01,P<0.001)。然而,我们注意到 30 天再入院的住院时间更短(5.78 天 vs 6.22 天,平均差异 1.2,95%置信区间:1.12-1.28,P<0.001),总住院费用更低(71076 美元 vs 93418 美元,平均差异 31452 美元,95%置信区间:29835-33069 美元,P<0.001)。与指数住院相比,年龄增长、CCI 评分较高、住院时间延长、胆道支架置入术和 ERCP 后出血是 30 天再入院住院死亡率的独立预测因素。
ERCP 后 30 天缓解率为 10.15%。与指数住院相比,30 天再入院的住院死亡率更高。